TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology
Rhea-AI Summary
TOMI (NASDAQ:TOMZ) received new regulatory approvals in Austria and Italy for its Binary Ionization Technology (BIT), advancing its European expansion. BIT is now authorized in Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Great Britain, and Northern Ireland under the EU Biocidal Products Regulation (BPR).
Approved as a PT2 disinfectant in the Netherlands since March 2026, BIT can use BPR’s mutual recognition process to streamline authorization in additional EU states. Parallel mutual recognition is anticipated for France, Ireland, Poland, Portugal, Romania, and Spain, supporting faster regional rollout.
Positive
- BIT newly authorized in Austria and Italy for disinfection use
- Technology now approved in nine European countries and regions
- BPR mutual recognition enables streamlined multi-country approvals
- PT2 disinfectant authorization in the Netherlands since March 2026
Negative
- Approvals still pending in France, Ireland, Poland, Portugal, Romania, Spain
News Market Reaction – TOMZ
On the day this news was published, TOMZ declined 3.70%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.4% during that session. Argus tracked a trough of -4.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $900K from the company's valuation, bringing the market cap to $23.44M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Pathogen market opportunity | Positive | -1.9% | Management spotlighted large food-safety decontamination opportunity across global produce supply chain. |
| May 27 | Market opportunity update | Positive | +1.2% | Expanded opportunity for SteraMist amid CDC hantavirus study and Ebola-related concerns. |
| May 22 | Outbreak demand commentary | Positive | +6.0% | Company highlighted rising demand tied to escalating Ebola outbreak and prior deployments. |
| May 19 | Technology mobilization | Positive | +4.4% | Mobilization of SteraMist iHP with RESPTCs and transport groups for rapid decontamination. |
| May 14 | System installation contract | Positive | -0.9% | Second SteraMist Hybrid System installation at a major East Coast research university. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent headlines have generally been positive, with three of the last five news events followed by gains and two by modest pullbacks, indicating mixed but often constructive reactions to operational updates and demand catalysts.
Over the past weeks, TOMI has repeatedly highlighted expanding use cases and demand for its SteraMist and related decontamination technologies. News has ranged from pathogen-driven opportunities and collaborations with treatment centers to new system installations at a major research university. Price reactions have been mixed, with several double-digit basis gains after outbreak-related updates but mild declines after some commercial or opportunity-focused releases. Today’s EU regulatory approvals extend this theme of geographic and application expansion across healthcare, research, and broader infrastructure environments.
Key Terms
binary ionization technology technical
biocidal products regulation (bpr) regulatory
mutual recognition regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
European Union Market Expansion Advances with Official Authorization in Austria and Italy
FREDERICK, Md., June 04, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, has secured official regulatory approval for its Binary Ionization Technology (BIT) in additional European Union member states. This milestone marks a significant step forward in the Company's European market expansion, with Austria and Italy joining the list of authorized countries. With these new additions, TOMI’s innovative disinfection product is now approved for use in Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Great Britain, and Northern Ireland. Notably, the product has been officially authorized as a PT2 disinfectant in the Netherlands since March 2026.
The regulatory milestone was achieved under the European Union’s Biocidal Products Regulation (BPR), which standardizes the authorization of biocidal products throughout the EU. Because the BPR allows an approval in one member state to support a streamlined mutual recognition process in others, TOMI can significantly accelerate its market rollout without repeating full, independent authorization procedures in every country. Looking ahead, parallel mutual recognition is anticipated to bring the technology to France, Ireland, Poland, Portugal, Romania, and Spain.
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the European market. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Zach Nevas
IMS Investor Relations
